{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:41:19Z","timestamp":1787020879342,"version":"build-2736575974"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:00:00Z","timestamp":1764115200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:00:00Z","timestamp":1764115200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","award":["NIHR200098"],"award-info":[{"award-number":["NIHR200098"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>At least 5 years of adjuvant endocrine therapy substantially reduces risks of recurrence and mortality in oestrogen-receptor positive early breast cancer. However, adherence to endocrine therapy is sub-optimal; poor adherence is associated with higher risks of recurrence and death from breast cancer, worse cancer-specific health-related quality-of-life, and increased healthcare costs. The SWEET randomised control trial aims to evaluate effectiveness and cost-effectiveness of the HT&amp;Me intervention in reducing poor adherence to adjuvant endocrine therapy and improve cancer-specific health-related quality-of-life in women with oestrogen-receptor positive early breast cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This is a UK based, pragmatic, open label randomised control trial. Participants (stages 1\u20133 oestrogen-receptor positive breast cancer, completed surgery, within 14 weeks of first endocrine therapy prescription;\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20091460) complete a baseline questionnaire, and are randomised to the HT&amp;Me intervention plus usual care, or usual care alone. The HT&amp;Me intervention is evidence-based, theory-informed and patient-centred. It consists of viewing an animation, two consultations with a SWEET study practitioner (a health care professional trained in delivering the intervention) approximately 3 months apart, access to the interactive HT&amp;Me web-app for the 18 months, and regular monthly nudges. All participants complete follow-up questionnaires at 6, 12, and 18 months. A multi-method process evaluation will be conducted involving quantitative analysis exploring mechanisms of action of the intervention, and qualitative interviews with a sample of participants and health care professionals involved in the trial. Primary endpoints are adjuvant endocrine therapy adherence (combined self-report (Medication Adherence Report Scale) and Proportion of Days Covered calculated from prescription encashment records) and cancer-specific health-related quality-of-life (Functional Assessment of Cancer Therapy Scale- General). Secondary endpoints are adjuvant endocrine therapy-specific health-related quality-of-life and within-trial cost-utility analysis which will evaluate cost-effectiveness.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>The SWEET trial seeks to address a significant issue affecting the growing population of breast cancer survivors: poor adherence to adjuvant endocrine therapy. Challenges addressed and resolved within the protocol include the following: capacity at sites to deliver the intervention; variations in breast cancer services nationally; and measuring adherence. This trial has potential to improve quality of life and adherence to endocrine therapy; reducing numbers of recurrences and breast cancer deaths, benefiting women, their families and the health service.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>ISRCTN Number: ISRCTN24852890 registered on 02.08.2023.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13063-025-09056-6","type":"journal-article","created":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T15:00:56Z","timestamp":1764169256000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Improving outcomeS for Women diagnosed with early breast cancer through adhErence to adjuvant Endocrine Therapy (SWEET): study protocol for a pragmatic randomised control trial of a patient-centred intervention to improve adherence to endocrine therapy in early breast cancer"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9226-5115","authenticated-orcid":false,"given":"Lucy","family":"McGeagh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Hiller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet","family":"Dunn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Wells","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Donnelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Wardley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Wolstenholme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Horne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah-Jane","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo","family":"Brett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitriona","family":"Cahir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Fenlon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Rose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lesley","family":"Turner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lyndsay","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Todd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Nicholson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phil","family":"Mawson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Norris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sue","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Dakin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raegan","family":"Barrows","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally","family":"Kum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Turner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farah","family":"Rehman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry","family":"Cain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eila","family":"Watson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Sharp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"SWEET Research Team","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Harmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicky","family":"Levitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Mann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin","family":"McCowan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoe","family":"Moon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mia","family":"Porteous","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel G.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,26]]},"reference":[{"key":"9056_CR1","unstructured":"Breast cancer\u2013IARC. www.iarc.who.int. Available from: https:\/\/www.iarc.who.int\/cancer-type\/breast-cancer\/"},{"key":"9056_CR2","doi-asserted-by":"crossref","unstructured":"Dowsett M, Cuzick J, Ingle J, Coates A, Forbes J, Bliss J, et al. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2010;28(3):509\u201318. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/19949017\/","DOI":"10.1200\/JCO.2009.23.1274"},{"issue":"9793","key":"9056_CR3","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/S0140-6736(11)60993-8","volume":"378","author":"Early Breast Cancer Trialists' Collaborative Group (EBCTCG)","year":"2011","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG). Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011;378(9793):771\u201384.","journal-title":"Lancet"},{"issue":"10001","key":"9056_CR4","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/S0140-6736(15)61074-1","volume":"386","author":"Early Breast Cancer Triallists Collaborative Group (EBCTCG)","year":"2015","unstructured":"Early Breast Cancer Triallists Collaborative Group (EBCTCG). Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet. 2015;386(10001):1341\u201352.","journal-title":"Lancet"},{"issue":"9869","key":"9056_CR5","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/S0140-6736(12)61963-1","volume":"381","author":"C Davies","year":"2013","unstructured":"Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 2013;381(9869):805\u201316.","journal-title":"Lancet"},{"issue":"3","key":"9056_CR6","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1056\/NEJMoa1604700","volume":"375","author":"PE Goss","year":"2016","unstructured":"Goss PE, Ingle JN, Pritchard KI, Robert NJ, Muss H, Gralow J, et al. Extending aromatase-inhibitor adjuvant therapy to 10 years. N Engl J Med. 2016;375(3):209\u201319.","journal-title":"N Engl J Med"},{"key":"9056_CR7","unstructured":"National institute for health and care excellence. Overview | Early and locally advanced breast cancer: diagnosis and management | Guidance | NICE. Nice.org.uk. NICE; 2018. https:\/\/www.nice.org.uk\/guidance\/ng101"},{"issue":"11","key":"9056_CR8","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1038\/sj.bjc.6604758","volume":"99","author":"C McCowan","year":"2008","unstructured":"McCowan C, Shearer J, Donnan PT, Dewar JA, Crilly M, Thompson AM, et al. Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer. Br J Cancer. 2008;99(11):1763\u20138.","journal-title":"Br J Cancer"},{"issue":"3","key":"9056_CR9","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1007\/s10549-009-0724-3","volume":"122","author":"MPP van Herk-Sukel","year":"2010","unstructured":"van Herk-Sukel MPP, van de Poll-Franse LV, Voogd AC, Nieuwenhuijzen GAP, Coebergh JWW, Herings RMC. Half of breast cancer patients discontinue tamoxifen and any endocrine treatment before the end of the recommended treatment period of 5 years: a population-based analysis. Breast Cancer Res Treat. 2010;122(3):843\u201351.","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"9056_CR10","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1007\/s10549-012-2114-5","volume":"134","author":"CC Murphy","year":"2012","unstructured":"Murphy CC, Bartholomew LK, Carpentier MY, Bluethmann SM, Vernon SW. Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review. Breast Cancer Res Treat. 2012;134(2):459\u201378.","journal-title":"Breast Cancer Res Treat"},{"key":"9056_CR11","doi-asserted-by":"publisher","first-page":"305","DOI":"10.2147\/PPA.S126651","volume":"11","author":"Z Moon","year":"2017","unstructured":"Moon Z, Moss-Morris R, Hunter MS, Carlisle S, Hughes LD. Barriers and facilitators of adjuvant hormone therapy adherence and persistence in women with breast cancer: a systematic review. Patient Prefer Adherence. 2017;11:305\u201322.","journal-title":"Patient Prefer Adherence"},{"issue":"9883","key":"9056_CR12","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1016\/S0140-6736(13)61235-0","volume":"381","author":"L Huiart","year":"2013","unstructured":"Huiart L, Ferdynus C, Giorgi R. Tamoxifen therapy for patients with breast cancer. Lancet. 2013;381(9883):2077.","journal-title":"Lancet"},{"issue":"7","key":"9056_CR13","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1038\/bjc.2013.116","volume":"108","author":"B Makubate","year":"2013","unstructured":"Makubate B, Donnan PT, Dewar JA, Thompson AM, McCowan C. Cohort study of adherence to adjuvant endocrine therapy, breast cancer recurrence and mortality. Br J Cancer. 2013;108(7):1515\u201324.","journal-title":"Br J Cancer"},{"issue":"1","key":"9056_CR14","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s10549-013-2422-4","volume":"138","author":"L Huiart","year":"2013","unstructured":"Huiart L, Ferdynus C, Giorgi R. A meta-regression analysis of the available data on adherence to adjuvant hormonal therapy in breast cancer: summarizing the data for clinicians. Breast Cancer Res Treat. 2013;138(1):325\u20138.","journal-title":"Breast Cancer Res Treat"},{"issue":"10","key":"9056_CR15","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1080\/08870446.2017.1296151","volume":"32","author":"C Cahir","year":"2017","unstructured":"Cahir C, Dombrowski SU, Kennedy MJ, Sharp L, Bennett K. Developing and validating a theoretical measure of modifiable influences on hormonal therapy medication taking behaviour in women with breast cancer. Psychol Health. 2017;32(10):1308\u201326.","journal-title":"Psychol Health"},{"issue":"5","key":"9056_CR16","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1038\/bjc.2013.464","volume":"109","author":"C McCowan","year":"2013","unstructured":"McCowan C, Wang S, Thompson AM, Makubate B, Petrie DJ. The value of high adherence to tamoxifen in women with breast cancer: a community-based cohort study. Br J Cancer. 2013;109(5):1172\u201380.","journal-title":"Br J Cancer"},{"key":"9056_CR17","doi-asserted-by":"crossref","unstructured":"Todd A, Waldron C, McGeagh L, Norris R, Bolnykh I, Stewart SJ. Identifying determinants of adherence to adjuvant endocrine therapy following breast cancer: a systematic review of reviews. Cancer Med. 20241;13(3):e6937. https:\/\/pubmed.ncbi.nlm.nih.gov\/38240343\/","DOI":"10.1002\/cam4.6937"},{"key":"9056_CR18","doi-asserted-by":"crossref","unstructured":"Bright EE, Finkelstein LB, Nealis MS, Genung SR, Wrigley J, Heng, et al. A systematic review and meta-analysis of interventions to promote adjuvant endocrine therapy adherence among breast cancer survivors. J Clin Oncol. 2023;41(28):4548\u201361.","DOI":"10.1200\/JCO.23.00697"},{"key":"9056_CR19","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.puhe.2016.03.030","volume":"136","author":"MP Kelly","year":"2016","unstructured":"Kelly MP, Barker M. Why is changing health-related behaviour so difficult? Public Health. 2016;136:109\u201316.","journal-title":"Public Health"},{"key":"9056_CR20","doi-asserted-by":"crossref","unstructured":"Rimmer B, Brown MC, Sotire T, Beyer F, Bolnykh I, Balla M, et al. Characteristics and components of self-management interventions for improving quality of life in cancer survivors: a systematic review. cancers. 2024;16(1):14. https:\/\/www.mdpi.com\/2072-6694\/16\/1\/14#","DOI":"10.3390\/cancers16010014"},{"issue":"1","key":"9056_CR21","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n2061","volume":"374","author":"K Skivington","year":"2021","unstructured":"Skivington K, Matthews L, Simpson SA, Craig P, Baird J, Blazeby JM, et al. A new framework for developing and evaluating complex interventions: update of medical research council guidance. BMJ. 2021;374(1):n2061.","journal-title":"BMJ"},{"key":"9056_CR22","unstructured":"National Institute for Health and Care Excellence. Overview | Medicines adherence: involving patients in decisions about prescribed medicines and supporting adherence | Guidance | NICE. Nice.org.uk. NICE; 2009. https:\/\/www.nice.org.uk\/Guidance\/CG76"},{"issue":"1","key":"9056_CR23","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1027\/1016-9040\/a000353","volume":"24","author":"R Horne","year":"2019","unstructured":"Horne R, Cooper V, Wileman V, Chan A. Supporting adherence to medicines for long-term conditions: a perceptions and practicalities approach based on an extended common-sense model. Eur Psychol. 2019;24(1):82\u201396.","journal-title":"Eur Psychol"},{"issue":"12","key":"9056_CR24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0080633","volume":"8","author":"R Horne","year":"2013","unstructured":"Horne R, Chapman SCE, Parham R, Freemantle N, Forbes A, Cooper V. Understanding patients\u2019 adherence-related beliefs about medicines prescribed for long-term conditions: a meta-analytic review of the necessity-concerns framework. PLoS One. 2013;8(12): e80633.","journal-title":"PLoS One"},{"key":"9056_CR25","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-023-07658-x","author":"C Cahir","year":"2023","unstructured":"Cahir C, Bennett K, Dombrowski SU, Kelly CM, Wells M, Watson E. Informing interventions to improve uptake of adjuvant endocrine therapy in women with breast cancer: a theoretical-based examination of modifiable influences on non-adherence. Support Care Cancer. 2023. https:\/\/doi.org\/10.1007\/s00520-023-07658-x.","journal-title":"Support Care Cancer"},{"key":"9056_CR26","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.breast.2023.05.007","volume":"70","author":"SJ Stewart","year":"2023","unstructured":"Stewart SJ, Slodkowska-Barabasz J, McGeagh L, Moon Z, Brett J, Wells M, et al. Development of the HT&me intervention to support women with breast cancer to adhere to adjuvant endocrine therapy and improve quality of life. Breast. 2023;70:32\u201340. https:\/\/doi.org\/10.1016\/j.breast.2023.05.007.","journal-title":"Breast"},{"key":"9056_CR27","unstructured":"McGeagh L, Stewart S, Norris R, Wells M, Thompson S, Mawson P, et al. Supporting women with adherence to adjuvant endocrine therapy (SWEET): feasibility study of the HT&Me intervention. EJON; 2025."},{"key":"9056_CR28","unstructured":"Committee for Human Medicinal Products (CHMP)., Guideline on multiplicity issues in clinical trials (Draft) (EMA\/CHMP\/44762\/2017). 2016, European Medicines Agency: London, UK."},{"key":"9056_CR29","unstructured":"Food and Drug Administration, Guidance for Industry. Multiple endpoints in clinical trials., U.S. Department of Health and Human Services Food and Drug Administration, Rockville, MD, USA"},{"issue":"1","key":"9056_CR30","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1080\/10543406.2017.1378668","volume":"28","author":"T Hamasaki","year":"2018","unstructured":"Hamasaki T, Evans SR, Asakura K. Design, data monitoring and analysis of clinical trials with co-primary endpoints: a review. J Biopharm Stat. 2018;28(1):28\u201351.","journal-title":"J Biopharm Stat"},{"issue":"7","key":"9056_CR31","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1111\/bcp.14193","volume":"86","author":"AHY Chan","year":"2020","unstructured":"Chan AHY, Horne R, Hankins M, Chisari C. The medication adherence report scale: a measurement tool for eliciting patients\u2019 reports of nonadherence. Br J Clin Pharmacol. 2020May 18;86(7):1281\u20138.","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"9056_CR32","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1200\/JCO.1993.11.3.570","volume":"11","author":"DF Cella","year":"1993","unstructured":"Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, et al. The functional assessment of cancer therapy scale: development and validation of the general measure. J Clin Oncol. 1993Mar;11(3):570\u20139.","journal-title":"J Clin Oncol"},{"issue":"3","key":"9056_CR33","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/s10549-007-9682-9","volume":"109","author":"D Cella","year":"2007","unstructured":"Cella D, Land SR, Chang CH, Day R, Costantino JP, Wolmark N, et al. Symptom measurement in the breast cancer prevention trial (BCPT) (P-1): psychometric properties of a new measure of symptoms for midlife women. Breast Cancer Res Treat. 2007Sep 13;109(3):515\u201326.","journal-title":"Breast Cancer Res Treat"},{"issue":"5","key":"9056_CR34","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.jval.2012.02.008","volume":"15","author":"B van Hout","year":"2012","unstructured":"van Hout B, Janssen MF, Feng YS, Kohlmann T, Busschbach J, Golicki D, et al. Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets. Value Health. 2012;15(5):708\u201315.","journal-title":"Value Health"},{"issue":"2","key":"9056_CR35","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1080\/08870440512331317670","volume":"20","author":"FF Sniehotta","year":"2005","unstructured":"Sniehotta FF, Scholz U, Schwarzer R. Bridging the intention\u2013behaviour gap: planning, self-efficacy, and action control in the adoption and maintenance of physical exercise. Psychol Health. 2005Apr;20(2):143\u201360.","journal-title":"Psychol Health"},{"issue":"10","key":"9056_CR36","first-page":"2851","volume":"22","author":"RA Shelby","year":"2014","unstructured":"Shelby RA, Edmond SN, Wren AA, Keefe FJ, Peppercorn JM, Marcom PK. Self-efficacy for coping with symptoms moderates the relationship between physical symptoms and well-being in breast cancer survivors taking adjuvant endocrine therapy. Support Care Cancer. 2014May 13;22(10):2851\u20139.","journal-title":"Support Care Cancer"},{"issue":"4","key":"9056_CR37","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1080\/08870446.2016.1275629","volume":"32","author":"Z Moon","year":"2017","unstructured":"Moon Z, Moss-Morris R, Hunter MS, Hughes LD. Measuring illness representations in breast cancer survivors (BCS) prescribed tamoxifen: modification and validation of the Revised Illness Perceptions Questionnaire (IPQ-BCS). Psychol Health. 2017J;32(4):439\u201358.","journal-title":"Psychol Health"},{"issue":"2","key":"9056_CR38","doi-asserted-by":"publisher","DOI":"10.1177\/2055102917740469","volume":"4","author":"J Brett","year":"2017","unstructured":"Brett J, Hulbert-Williams NJ, Fenlon D, Boulton M, Walter FM, Donnelly P, et al. Psychometric properties of the beliefs about medicine questionnaire\u2013adjuvant endocrine therapy (BMQ-AE) for women taking AETs following early-stage breast cancer. Health Psychol Open. 2017;4(2): 205510291774046.","journal-title":"Health Psychol Open"},{"issue":"3","key":"9056_CR39","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1136\/qhc.0100135","volume":"10","author":"R Horne","year":"2001","unstructured":"Horne R, Hankins M, Jenkins R. The satisfaction with information about medicines scale (SIMS): a new measurement tool for audit and research. Qual Saf Health Care. 2001;10(3):135\u201340.","journal-title":"Qual Saf Health Care"},{"issue":"1","key":"9056_CR40","first-page":"18","volume":"4","author":"G Godin","year":"2011","unstructured":"Godin G. The Godin-shephard leisure-time physical activity questionnaire. Health Fit J Can. 2011;4(1):18\u201322.","journal-title":"Health Fit J Can"},{"issue":"1","key":"9056_CR41","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s11764-014-0384-0","volume":"9","author":"C Foster","year":"2014","unstructured":"Foster C, Breckons M, Cotterell P, Barbosa D, Calman L, Corner J, et al. Cancer survivors\u2019 self-efficacy to self-manage in the year following primary treatment. J Cancer Surviv. 2014;9(1):11\u20139.","journal-title":"J Cancer Surviv"},{"key":"9056_CR42","unstructured":"NHS England. The healthcare ecosystem. NHS Digital. 2022. https:\/\/digital.nhs.uk\/developer\/guides-and-documentation\/introduction-to-healthcare-technology\/the-healthcare-ecosystem"},{"key":"9056_CR43","unstructured":"Breast Cancer Now. Breast cancer research and care charity | Breast Cancer Now. Breast Cancer Now. 2019. https:\/\/breastcancernow.org"},{"issue":"1","key":"9056_CR44","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s12160-013-9486-6","volume":"46","author":"S Michie","year":"2013","unstructured":"Michie S, Richardson M, Johnston M, Abraham C, Francis J, Hardeman W. The behavior change technique taxonomy (v1) of 93 hierarchically clustered techniques: building an international consensus for the reporting of behavior change interventions. Ann Behav Med. 2013;46(1):81\u201395.","journal-title":"Ann Behav Med"},{"key":"9056_CR45","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/217047","volume":"2015","author":"WY Lam","year":"2015","unstructured":"Lam WY, Fresco P. Medication adherence measures: an overview. BioMed Res Int. 2015;2015: 2015(217047):1\u201312.","journal-title":"BioMed Res Int"},{"key":"9056_CR46","unstructured":"Hughes L. Personal communication: MARS 5 and PDC adherence. 2025."},{"key":"9056_CR47","unstructured":"Hall P, Hulme C. UK Cancer Costs Questionnaire UKCC Version 2. http:\/\/www.dirum.org\/assets\/downloads\/ukcc_v2.pdf"},{"key":"9056_CR48","doi-asserted-by":"crossref","unstructured":"Gale NK, Heath G, Cameron E, Rashid S, Redwood S. Using the framework method for the analysis of qualitative data in multi-disciplinary health research. BMC Med Res Methodol. 2013;13(1):1\u20138. https:\/\/bmcmedresmethodol.biomedcentral.com\/articles\/10.1186\/1471-2288-13-117","DOI":"10.1186\/1471-2288-13-117"},{"issue":"7","key":"9056_CR49","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1007\/s00432-017-2372-z","volume":"143","author":"J Geissler","year":"2017","unstructured":"Geissler J, Sharf G, Bombaci F, Daban M, Jong JD, Gavin T, et al. Factors influencing adherence in CML and ways to improvement: results of a patient-driven survey of 2546 patients in 63 countries. J Cancer Res Clin Oncol. 2017Mar 13;143(7):1167\u201376.","journal-title":"J Cancer Res Clin Oncol"},{"key":"9056_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejon.2020.101822","volume":"48","author":"Y Chen","year":"2020","unstructured":"Chen Y, Wu X, Xian X, Zhang Y, Gong N, Qin H, et al. Adherence to oral chemotherapy among colorectal cancer patients: a longitudinal study. Eur J Oncol Nurs. 2020;48: 101822.","journal-title":"Eur J Oncol Nurs"},{"issue":"3","key":"9056_CR51","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.jgo.2021.11.006","volume":"13","author":"BM Hicks","year":"2022","unstructured":"Hicks BM, Chun DS, Peacock Hinton S, Hsu CD, Tan HJ, Lund JL. Patterns of first-line targeted therapy utilization and adherence among older adults diagnosed with metastatic renal cell carcinoma. J Geriatr Oncol. 2022;13(3):325\u201333.","journal-title":"J Geriatr Oncol"},{"issue":"5","key":"9056_CR52","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1007\/s11096-020-01083-4","volume":"42","author":"N Matti","year":"2020","unstructured":"Matti N, Delon C, Rybarczyk-Vigouret M-C, Khan GM, Beck M, Michel B. Adherence to oral anticancer chemotherapies and estimation of the economic burden associated with unused medicines. Int J Clin Pharm. 2020;42(5):1311\u20138.","journal-title":"Int J Clin Pharm"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-025-09056-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-025-09056-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-025-09056-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T15:01:02Z","timestamp":1764169262000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-025-09056-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,26]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["9056"],"URL":"https:\/\/doi.org\/10.1186\/s13063-025-09056-6","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,26]]},"assertion":[{"value":"13 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was provided by South Central - Hampshire B Research Ethics Committee 11.08.2023. Written, informed consent to participate will be obtained from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate {24}"}},{"value":"Not applicable\u2014details, images, or videos relating to an individual person are not included.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication {32}"}},{"value":"All authors have declared no competing interests, with the exception of the following:FR discloses honoraria from Pfizer and Astra Zeneca\/Daiichi Sankyo.HC reports Roche Medical. Ad Board, support with Travel, Honorarium for speaking, Research Grant.; Astra Zeneca. Ad Board, Honorarium for speaking; Exact Health. Honorarium for speaking, Ad board, Research grant; Pfizer. Honorarium for speaking; Baxter. Honorarium for speaking, Ad Board; Lilly. Ad Board; Veracyte. Ad board; Allergan. Speaking and meeting support; MSD. Honorarium for speaking and Ad Board and Novartis. Ad Board.RH reports speaker engagement with honoraria for AbbVie, Abbott, Amgen, Astellas, AstraZeneca, Boehringer Ingelheim, Biogen, Gilead Sciences, GlaxoSmithKline, Janssen, Merck Sharp Dohme, Merck, Novartis, Pfizer, Procter & Gamble, Roche, Sanofi, Shire Pharmaceuticals, TEVA, UCB, personal consultancy for Amgen, Abbott, AstraZeneca and Novartis. He is the Founding Director of a UCL-Business company (Spoonful of Sugar Ltd) providing consultancy on treatment engagement and patient support programmes to healthcare policy makers, providers and pharmaceutical industry.SH works for Breast Cancer Now (who are providing nurse support for the RCT).SS reports personal consultancy to Lilly.VH has received travel grants from TiLoop, speaker fee from Digistain limited and Roche, consultancy fee from Medscape, Novartis, Gilead and Bioderma and has been a nurse rep for OPTIMA.ZM reports paid work for UCL Business Company Spoonful of Sugar Ltd.No other relationships or activities have been declared that could appear to have influenced the submitted work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests {28}"}}],"article-number":"551"}}